Mymetics Corp. receives over $9 million for virosome-based vaccine research
The researchers, based at Mymetics BV, will use more than $5 million to fund Horizon 2020, which is the research and innovation program based in the European Union (E.U.). Another sum exceeding $3 million will be allocated to the Swiss State Secretariat for Education, Research and Innovation (SERI) for the team’s research partners based in Switzerland.
"With more than 90 percent of the existing vaccines dependent on the cold-chain and the resulting detrimental impact on availability, efficacy and costs of these vaccines in developing countries, there is an undisputable need to innovate and manufacture vaccines that are stable and temperature independent,” Mymetics CEO Ronald Kempers said. "We are very pleased that our virosome vaccine technology and know-how has been recognized together with the skills and expertise of our E.U. consortium partners. Funding this project can represent a major innovation in vaccine development."
Overall, the funds will assist in evaluating, creating and producing scale-ups of thermos-stable and cold-chain independent nano-pharmaceutical virosome-based vaccine candidates.
"We are very thankful for the E.U. Horizon 2020 and Swiss funding organizations to finance this very important innovation project in the world of vaccines,” Mymetics chief science officer and MACIVIVA project coordinator Sylvain Fleury said. “We look forward to work with our consortium partners to start the efforts on our promising virosome-based HIV vaccine candidate, with the overall objective to make this scalable and applicable for all our virosome based vaccines."